Satisfactory Six Months At NeuroSearch

1 September 1996

Profits at the Danish company NeuroSearch were 19 million Danish kroner ($3.3 million) in the first six months of 1996.

This was considerably more than expected and was caused by an unintended accrual of income, said the company. This is expected to equal out during the rest of the year. Income and expenses should lead to a result for the year on the same level as in 1995, which was 4.5 million kroner, the firm said in a statement.

Revenues for the first six months of 1996 were 43 million kroner, compared with 12.5 million kroner a year earlier. Spending on R&D amounted to 19 million kroner, up 2.1%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight